194 related articles for article (PubMed ID: 34155235)
21. CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.
Picanço-Castro V; Swiech K; Malmegrim KCR; Covas DT
Methods Mol Biol; 2020; 2086():1-10. PubMed ID: 31707664
[TBL] [Abstract][Full Text] [Related]
22. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
23. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
24. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
[TBL] [Abstract][Full Text] [Related]
25. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
[TBL] [Abstract][Full Text] [Related]
26. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
[TBL] [Abstract][Full Text] [Related]
27. Generation of Chimeric Antigen Receptor T Cells Using Gammaretroviral Vectors.
Mo F; Mamonkin M
Methods Mol Biol; 2020; 2086():119-130. PubMed ID: 31707671
[TBL] [Abstract][Full Text] [Related]
28. Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells.
Loureiro LR; Feldmann A; Bergmann R; Koristka S; Berndt N; Arndt C; Pietzsch J; Novo C; Videira P; Bachmann M
Blood Cancer J; 2018 Aug; 8(9):81. PubMed ID: 30190468
[No Abstract] [Full Text] [Related]
29. Interleukin-23 engineering improves CAR T cell function in solid tumors.
Ma X; Shou P; Smith C; Chen Y; Du H; Sun C; Porterfield Kren N; Michaud D; Ahn S; Vincent B; Savoldo B; Pylayeva-Gupta Y; Zhang S; Dotti G; Xu Y
Nat Biotechnol; 2020 Apr; 38(4):448-459. PubMed ID: 32015548
[TBL] [Abstract][Full Text] [Related]
30. Insights on Droplet Digital PCR-Based Cellular Kinetics and Biodistribution Assay Support for CAR-T Cell Therapy.
Sugimoto H; Chen S; Minembe JP; Chouitar J; He X; Wang H; Fang X; Qian MG
AAPS J; 2021 Mar; 23(2):36. PubMed ID: 33655393
[TBL] [Abstract][Full Text] [Related]
31. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
32. High-Throughput Flow Cytometric Method for the Simultaneous Measurement of CAR-T Cell Characterization and Cytotoxicity against Solid Tumor Cell Lines.
Martinez EM; Klebanoff SD; Secrest S; Romain G; Haile ST; Emtage PCR; Gilbert AE
SLAS Discov; 2018 Aug; 23(7):603-612. PubMed ID: 29634393
[TBL] [Abstract][Full Text] [Related]
33. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
34. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
[TBL] [Abstract][Full Text] [Related]
35. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
[TBL] [Abstract][Full Text] [Related]
36. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
37. TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells.
Li D; Hu Y; Jin Z; Zhai Y; Tan Y; Sun Y; Zhu S; Zhao C; Chen B; Zhu J; Chen Z; Chen S; Li J; Liu H
Leukemia; 2018 Sep; 32(9):2012-2016. PubMed ID: 30046161
[No Abstract] [Full Text] [Related]
38. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy.
Rashidijahanabad Z; Huang X
Semin Immunol; 2020 Feb; 47():101390. PubMed ID: 31982247
[TBL] [Abstract][Full Text] [Related]
40. Antagonism of IAPs Enhances CAR T-cell Efficacy.
Michie J; Beavis PA; Freeman AJ; Vervoort SJ; Ramsbottom KM; Narasimhan V; Lelliott EJ; Lalaoui N; Ramsay RG; Johnstone RW; Silke J; Darcy PK; Voskoboinik I; Kearney CJ; Oliaro J
Cancer Immunol Res; 2019 Feb; 7(2):183-192. PubMed ID: 30651288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
